MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. / Comi, Giancarlo; Cook, Stuart D; Giovannoni, Gavin; Rammohan, Kottil; Rieckmann, Peter; Sørensen, Per Soelberg; Vermersch, Patrick; Hamlett, Anthony C; Viglietta, Vissia; Greenberg, Steven J.

I: Journal of Neurology, 2013.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Comi, G, Cook, SD, Giovannoni, G, Rammohan, K, Rieckmann, P, Sørensen, PS, Vermersch, P, Hamlett, AC, Viglietta, V & Greenberg, SJ 2013, 'MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study', Journal of Neurology. https://doi.org/10.1007/s00415-012-6775-0

APA

Comi, G., Cook, S. D., Giovannoni, G., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Hamlett, A. C., Viglietta, V., & Greenberg, S. J. (2013). MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. Journal of Neurology. https://doi.org/10.1007/s00415-012-6775-0

Vancouver

Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS o.a. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. Journal of Neurology. 2013. https://doi.org/10.1007/s00415-012-6775-0

Author

Comi, Giancarlo ; Cook, Stuart D ; Giovannoni, Gavin ; Rammohan, Kottil ; Rieckmann, Peter ; Sørensen, Per Soelberg ; Vermersch, Patrick ; Hamlett, Anthony C ; Viglietta, Vissia ; Greenberg, Steven J. / MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. I: Journal of Neurology. 2013.

Bibtex

@article{40011d8cf57542a2af40f500161bb913,
title = "MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study",
abstract = "We herein provide a comprehensive assessment of magnetic resonance imaging (MRI) outcomes from CLARITY, a 96-week, double-blind study demonstrating significant clinical and MRI improvements in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets. Patients with RRMS were randomized 1:1:1 to annual short-course therapy with cladribine tablets cumulative dose 3.5 or 5.25 mg/kg or placebo. MRI endpoints included mean number of T1 gadolinium-enhancing (Gd+), active T2 and combined unique (CU) lesions/patient/scan. MRI-measured disease activity was significantly reduced in both cladribine tablets groups versus placebo. The proportion of patients with no active lesions at study end was: T1 Gd+ lesions: 86.8 and 91.0 versus 48.3 % (p ",
author = "Giancarlo Comi and Cook, {Stuart D} and Gavin Giovannoni and Kottil Rammohan and Peter Rieckmann and S{\o}rensen, {Per Soelberg} and Patrick Vermersch and Hamlett, {Anthony C} and Vissia Viglietta and Greenberg, {Steven J}",
year = "2013",
doi = "10.1007/s00415-012-6775-0",
language = "English",
journal = "Deutsche Zeitschrift fur Nervenheilkunde",
issn = "0939-1517",
publisher = "Springer Medizin",

}

RIS

TY - JOUR

T1 - MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

AU - Comi, Giancarlo

AU - Cook, Stuart D

AU - Giovannoni, Gavin

AU - Rammohan, Kottil

AU - Rieckmann, Peter

AU - Sørensen, Per Soelberg

AU - Vermersch, Patrick

AU - Hamlett, Anthony C

AU - Viglietta, Vissia

AU - Greenberg, Steven J

PY - 2013

Y1 - 2013

N2 - We herein provide a comprehensive assessment of magnetic resonance imaging (MRI) outcomes from CLARITY, a 96-week, double-blind study demonstrating significant clinical and MRI improvements in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets. Patients with RRMS were randomized 1:1:1 to annual short-course therapy with cladribine tablets cumulative dose 3.5 or 5.25 mg/kg or placebo. MRI endpoints included mean number of T1 gadolinium-enhancing (Gd+), active T2 and combined unique (CU) lesions/patient/scan. MRI-measured disease activity was significantly reduced in both cladribine tablets groups versus placebo. The proportion of patients with no active lesions at study end was: T1 Gd+ lesions: 86.8 and 91.0 versus 48.3 % (p 

AB - We herein provide a comprehensive assessment of magnetic resonance imaging (MRI) outcomes from CLARITY, a 96-week, double-blind study demonstrating significant clinical and MRI improvements in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets. Patients with RRMS were randomized 1:1:1 to annual short-course therapy with cladribine tablets cumulative dose 3.5 or 5.25 mg/kg or placebo. MRI endpoints included mean number of T1 gadolinium-enhancing (Gd+), active T2 and combined unique (CU) lesions/patient/scan. MRI-measured disease activity was significantly reduced in both cladribine tablets groups versus placebo. The proportion of patients with no active lesions at study end was: T1 Gd+ lesions: 86.8 and 91.0 versus 48.3 % (p 

U2 - 10.1007/s00415-012-6775-0

DO - 10.1007/s00415-012-6775-0

M3 - Journal article

C2 - 23263473

JO - Deutsche Zeitschrift fur Nervenheilkunde

JF - Deutsche Zeitschrift fur Nervenheilkunde

SN - 0939-1517

ER -

ID: 48584619